Table 4.
Association of HPV16 E6 gene mutations with clinicopathological features of cervical cancer.
| E6 mutations | E6 unmutated | P value | |
|---|---|---|---|
| Total n | 19 | 10 | |
| FIGO stage n (%) | |||
| I | 14 (73.7) | 9 (90.0) | .35 |
| II | 1 (5.3) | 1 (10.0) | |
| III | 4 (21.1) | 0 (0.0) | |
| Pathological type n (%) | |||
| Squamous carcinoma | 15 (78.9) | 9 (90.0) | >.99 |
| Adenocarcinoma | 3 (15.8) | 1 (10.0) | |
| Adenosquamous carcinoma | 1 (5.3) | 0 (0.0) | |
| Vascular metastasis n (%) | |||
| + | 9 (47.4) | 5 (50.0) | >.99 |
| − | 9 (47.4) | 5 (50.0) | |
| Unknown | 1 (5.3) | 0 (0.0) | |
| Lymph node metastasis n (%) | |||
| + | 5 (26.3) | 2 (20.0) | >.99 |
| − | 13 (68.4) | 8 (80.0) | |
| Unknown | 1 (5.3) | 0 (0.0) |
FIGO = International Federation of Gynecology and Obstetrics.